Table 2 Frequency of antimicrobial use among CCRT patients by group
Cases N = 157 | Control N = 158 | Total N = 315 | p-value | |
|---|---|---|---|---|
Overall antimicrobial use | ||||
At any point | 157 (100.0%) | 138 (87.3%) | 295 (93.7%) | < 0.001 |
Before CCRT activation | 129 (82.2%) | 111 (70.3%) | 240 (76.2%) | 0.013 |
During CCRT activation | 151 (96.2%) | 103 (65.2%) | 254 (80.6%) | < 0.001 |
After CCRT activation | 129 (82.2%) | 107 (67.7%) | 236 (74.9%) | 0.003 |
Individual antimicrobial use at any point | ||||
Meropenem | 107 (68.2%) | 55 (34.8%) | 162 (51.4%) | < 0.001 |
Vancomycin | 89 (56.7%) | 41 (25.9%) | 130 (41.3%) | < 0.001 |
Piperacillin-tazobactam | 44 (28.0%) | 46 (29.1%) | 90 (28.6%) | 0.831 |
Ceftriaxone | 16 (10.2%) | 22 (13.9%) | 38 (12.1%) | 0.311 |
Linezolid | 21 (13.4%) | 6 (3.8%) | 27 (8.6%) | 0.002 |
Colistin | 13 (8.3%) | 10 (6.3%) | 23 (7.3%) | 0.506 |
Caspofungin | 18 (11.5%) | 3 (1.9%) | 21 (6.7%) | 0.001 |
Anidulafungin | 14 (8.9%) | 4 (2.5%) | 18 (5.7%) | 0.015 |
Tigecycline | 12 (7.6%) | 5 (3.2%) | 17 (5.4%) | 0.079 |
Ciprofloxacin | 6 (3.8%) | 11 (7.0%) | 17 (5.4%) | 0.218 |
Imipenem | 8 (5.1%) | 6 (3.8%) | 14 (4.4%) | 0.576 |
Others | 137 (87.3%) | 85 (53.8%) | 222 (70.5%) | < 0.001 |
Antimicrobial change after CCRT activation | ||||
New prescription | 254 (45.4%) | 117 (36.6%) | 371 (42.2%) | 0.010 |
Continuation | 305 (54.6%) | 203 (63.4%) | 508 (57.8%) | |